Biostatistics in Clinical Research

Interim Analysis in Clinical Trials: Strategies, Regulatory Considerations, and Best Practices

Posted on digi By digi

Interim Analysis refers to the examination of accumulating data from an ongoing clinical trial before its formal completion. It allows for early decisions regarding continuation, modification, or termination of the study based on predefined statistical and clinical criteria. Interim analyses are essential for protecting participant welfare, optimizing trial efficiency, and informing regulatory decisions under strict control mechanisms to maintain study integrity.
Click to read the full article.

Biostatistics in Clinical Research, Interim Analysis

Statistical Analysis Plans (SAP) in Clinical Trials: Essential Guide to Development and Best Practices

Posted on digi By digi

A Statistical Analysis Plan (SAP) is a detailed, technical document developed before the database lock that outlines the planned statistical analyses of a clinical trial’s data. It serves as a bridge between the study protocol and the final statistical outputs, ensuring that the analyses align with study objectives while maintaining objectivity and regulatory compliance.
Click to read the full article.

Biostatistics in Clinical Research, Statistical Analysis Plans

Handling Missing Data in Clinical Trials: Strategies, Methods, and Regulatory Considerations

Posted on digi By digi

Handling Missing Data involves understanding the mechanisms that lead to missingness, choosing appropriate statistical techniques to minimize bias, and transparently reporting missing data handling strategies in clinical trial documentation. Proactive planning, careful analysis, and regulatory-aligned methodologies are essential to mitigate the impact of missing data on trial outcomes and conclusions.
Click to read the full article.

Biostatistics in Clinical Research, Handling Missing Data

Sample Size Determination in Clinical Trials: Key Concepts, Methods, and Best Practices

Posted on digi By digi

Sample size determination involves estimating the minimum number of participants needed to reliably detect a pre-specified treatment effect with an acceptable probability (power) while controlling the risk of Type I error. It balances the need for statistical rigor with ethical and operational considerations, ensuring that trials are neither underpowered (risking inconclusive results) nor overpowered (wasting resources and exposing too many subjects).
Click to read the full article.

Biostatistics in Clinical Research, Sample Size Determination

Biostatistics in Clinical Research: Foundations, Applications, and Best Practices

Posted on digi By digi

Biostatistics is the application of statistical principles and methodologies to biological, medical, and clinical data. In clinical research, biostatistics ensures that data collection, analysis, and interpretation processes are scientifically sound and capable of answering research questions while minimizing bias, variability, and uncertainty. Biostatistics supports critical functions including study design, sample size calculation, interim monitoring, final analyses, and result dissemination.
Click to read the full article.

Biostatistics in Clinical Research

Survival Analysis in Clinical Trials: Key Methods, Applications, and Best Practices

Posted on digi By digi

Survival Analysis encompasses statistical methods designed to analyze time-to-event data, where the outcome is the time until an event of interest occurs (e.g., death, disease progression). Unlike other types of data, survival data are often censored, meaning the exact event time may not be observed for all participants, requiring specialized analytical approaches that account for incomplete observations.
Click to read the full article.

Biostatistics in Clinical Research, Survival Analysis

What to Include in a Statistical Analysis Plan (SAP) for Clinical Trials

Posted on digi By digi

An SAP is a detailed, standalone document that supplements the clinical trial protocol. It defines the statistical techniques, models, and outputs that will be used to analyze primary and secondary endpoints, safety data, and exploratory objectives. According to USFDA and ICH E9 guidelines, the SAP should be finalized before database lock and unblinding of data.
Click to read the full article.

Biostatistics in Clinical Research, Statistical Analysis Plans